Skip to main content
Quest Diagnostics

Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US

Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US

Authors: Lehman JS, Fernandez AP, Leiferman KM, Brinster NK, Culton DA, Kim RH, North JP, Stoff BK, Camilleri MJ, Cocks MM, Elenitsas R, Fung MA, Grover RK, Jedrych JJ, Kuechle MK, McNiff JM, Moshiri AS, Motaparthi K, Murphy MJ, Nousari CH, Shalin SC, Zone JJ, Bridges AG

Citation: JAMA Dermatol. 2025 Apr 2. doi: 10.1001/jamadermatol.2025.0339. Online ahead of print.

Specialties:  Dermatology

Disclaimer: One or more of the authors of this publication were employed at the time by DermPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content

Publication
Perspectives on Use of the Cutaneous Direct Immunofluorescence Assay

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.